Company intelligence / Profile preview

CureDM, Inc.

Wynnewood, Pennsylvania, United Statescuredm.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CureDM developed a novel human peptide ("HIP" or "HIP2B") that stimulates differentiation of new insulin-producing pancreatic islets from adult progenitor cells. The approach aims to restore endogenous insulin production and potentially allow discontinuation of exogenous insulin therapy for diabetes patients. As of the latest available information, their lead compound was advancing through preclinical studies with plans for IND submission but no published clinical results yet[1][3].

Therapeutic areas: Endocrinology
Modalities: Peptides (notably Human proIslet Peptide/HIP2B)
Industry: Biotech

Drug pipeline

1 asset

HIP2B

Pre-clinical

Indications: Diabetes

Partnerships

Sanofi-Aventis partnered with CureDM to develop its novel diabetes treatment candidate PancreateTM[4]University of Pennsylvania Human Islet LaboratoryCalvert Research Institute/Calvert HoldingsScientific Health Development Ltd.[3]

Beyond the preview

Go deeper on CureDM, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CureDM, Inc..